Michael Gelband’s Supernus Pharmaceuticals SUPN Stock Holding History

Michael Gelband’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$465K	Sell	9,998 -192,118	-95%	-$9.23M	﹤0.01%	1260
2026 Q1	$10.4M	Sell	202,116 -27,010	-12%	-$1.38M	0.08%	220
2025 Q4	$11.4M	Buy	+229,126	New	+$11.1M	0.09%	225
2023 Q2	–	Sell	-47,421	Closed	-$1.72M	–	2233
2023 Q1	$1.72M	Buy	+47,421	New	+$1.82M	0.01%	947
2022 Q2	–	Sell	-33,343	Closed	-$1.08M	–	2431
2022 Q1	$1.08M	Sell	33,343 -2,527	-7%	-$77.5K	0.01%	1098
2021 Q4	$1.05M	Buy	+35,870	New	+$1.09M	0.01%	1045

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Michael Gelband's SUPN Position: Q2 2026 in Review

Michael Gelband reduced its Supernus Pharmaceuticals (SUPN) stake by 95% in Q2 2026, selling an estimated $9.23M and leaving 9,998 shares worth $465K. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Michael Gelband first reported a position in SUPN in Q4 2021 and has held it in 6 quarters since. The position peaked at $11.4M in Q4 2025. 331 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Michael Gelband held 9,998 shares of Supernus Pharmaceuticals worth $465K as of Q2 2026.
Michael Gelband sold 192,118 Supernus Pharmaceuticals shares in Q2 2026, an estimated $9.23M.
Supernus Pharmaceuticals made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1260 holding.
Michael Gelband first reported a position in Supernus Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
Michael Gelband's Supernus Pharmaceuticals position peaked at $11.4M in Q4 2025.
331 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.